Progress and summary of recent congress: ASCO-GU, EAU, AUA, ASCO about the medical management of locally advanced or metastatic kidney cancer.
Fiche publication
Date publication
mars 2010
Auteurs
Membres identifiés du Cancéropôle Est :
Pr LANG Hervé
Tous les auteurs :
Patard JJ, Escudier B, Paparel P, Neuzillet Y, Long JA, Baumert H, Correas JM, Lang H, Poissonnier L, Rioux-Leclercq N, Soulie M
Lien Pubmed
Résumé
During the recent congress of urology and oncology key topics discussed were the evolution of survival data in metastatic kidney cancer which median is now around 40 months, persistent questions about the role of nephrectomy, including access to the systemic treatment of nephrectomized patients and tumor resectability induced by systemic therapies, the emergence of new prognostic models which are adapted to new therapeutic standards, and the emergence of promising new drugs including pazopanib. This article describes these advances. (C) 2010 Published by Elsevier Masson SAS.
Référence
Prog Urol. 2010 Mar;20 Suppl 1:S11-5